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BACKGROUND: Studies have reported significant reduction in acute myocardial infarction–related hospitalizations during the 
coronavirus disease 2019 (COVID-19) pandemic. However, whether these trends are associated with increased incidence of 
out-of-hospital cardiac arrest (OHCA) in this population is unknown.
METHODS AND RESULTS: Acute myocardial infarction hospitalizations with OHCA during the COVID-19 period (February 1–May 
14, 2020) from the Myocardial Ischaemia National Audit Project and British Cardiovascular Intervention Society data sets were 
analyzed. Temporal trends were assessed using Poisson models with equivalent pre–COVID-19 period (February 1–May 14, 
2019) as reference. Acute myocardial infarction hospitalizations during COVID-19 period were reduced by >50% (n=20 310 
versus n=9325). OHCA was more prevalent during the COVID-19 period compared with the pre–COVID-19 period (5.6% ver-
sus 3.6%), with a 56% increase in the incidence of OHCA (incidence rate ratio, 1.56; 95% CI, 1.39–1.74). Patients experiencing 
OHCA during COVID-19 period were likely to be older, likely to be women, likely to be of Asian ethnicity, and more likely to 
present with ST-segment–elevation myocardial infarction. The overall rates of invasive coronary angiography (58.4% versus 
71.6%; P<0.001) were significantly lower among the OHCA group during COVID-19 period with increased time to reperfusion 
(mean, 2.1 versus 1.1 hours; P=0.05) in those with ST-segment–elevation myocardial infarction. The adjusted in-hospital mor-
tality probability increased from 27.7% in February 2020 to 35.8% in May 2020 in the COVID-19 group (P<.001).
CONCLUSIONS: In this national cohort of hospitalized patients with acute myocardial infarction, we observed a significant in-
crease in incidence of OHCA during COVID-19 period paralleled with reduced access to guideline-recommended care and 
increased in-hospital mortality.
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During the global pandemic of coronavirus dis-ease 2019 (COVID-19), caused by the novel se-vere acute respiratory syndrome coronavirus 2, a significant reduction in acute myocardial infarction (AMI)–related hospitalizations has been observed.1–4 It has been postulated that patients with AMI are not 
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seeking medical attention because of their concerns 
about the risk of nosocomial-acquired COVID-19 infec-
tion, as well as limitations to social movement attrib-
utable to government lockdowns.3,5,6 Delays to timely 
reperfusion are associated with an increased risk of 
life-threatening arrhythmias, out-of-hospital cardiac ar-
rest (OHCA), heart failure, and death among patients 
presenting with AMI.7–9
A recent multicenter observational report from Italy 
found that AMI-related hospitalizations were reduced 
by almost 50% during the COVID-19 period and ac-
companied by a 3-fold increase in mortality and com-
plications.2 Such significant changes to AMI-related 
hospitalizations may result in an increase in OHCA and 
death.10,11 Data from the Lombardia CARe (Lombardia 
Cardiac Arrest Registry) reported a 58% increase in 
OHCA during the first 40 days of the COVID-19 out-
break.12 It was thought that this may be related to the 
spread of the COVID-19 infection as there was no in-
formation about the incidence of AMI in this cohort. 
Similar observations were made by Lai et al from New 
York City emergency medical services system, where 
a 3-fold increase in incidence of OHCA was noted in 
those undergoing emergency medical services resus-
citation during the COVID-19 period.13 It remains un-
clear, however, whether reduced hospitalizations with 
AMI are associated with changes in incident OHCA. 
Equally, it is not known if the changes in service struc-
ture and delivery of healthcare emergency response 
during the COVID-19 pandemic have influenced the 
management of patients presenting with OHCA in the 
context of AMI. Using multisource nationwide data de-
rived from UK national acute coronary syndrome and 
percutaneous coronary intervention (PCI) data sets, 
we studied the characteristics, care, and outcomes 
of admissions to hospital with AMI complicated by 




Because of the sensitive nature of the data collected 
for this study, requests to access the data set from 
qualified researchers trained in human subject confi-
dentiality protocols may be sent to National Institute 
of Cardiovascular Outcomes Research. Data for this 
study were drawn from 2 nationwide cardiovascu-
lar registries of National Institute of Cardiovascular 
Outcomes Research (namely, the MINAP [Myocardial 
Ischaemia National Audit Project] registry and the 
BCIS [British Cardiovascular Intervention Society] 
registry PCI data set).14,15 Full details on the frame-
work of these data sets and their utility in conduct-
ing research have been described previously.16–18 
Briefly, the MINAP registry is one of the largest sin-
gle health system heart attack registries and collects 
information about baseline demographics, reperfu-
sion treatment, and pharmacological and invasive 
management of patients admitted with AMI to 1 of 
the 195 acute National Health System hospitals in 
England.19–21 The BCIS registry PCI database con-
tains high-resolution information about the proce-
dural aspects, periprocedural pharmacology, and 
in-hospital PCI-related complications of patients ad-
mitted with AMI.16,22,23
Ethics
The National Institute of Cardiovascular Outcomes 
Research databases, including MINAP and BCIS reg-
istries, are collected and used for research purposes 
without requiring informed patient consent, which 
fell under section 251 of National Health Service Act 
CLINICAL PERSPECTIVE
What Is New?
• This population-based cohort study provides 
important information about the incidence and 
clinical and procedural characteristics of pa-
tients presenting with acute myocardial infarc-
tion and prehospital cardiac arrest during the 
coronavirus disease 2019 (COVID-19) pandemic 
in England.
• There was a marked increase in the incidence of 
out-of-hospital cardiac arrest during the COVID-
19 pandemic compared with the pre–COVID-19 
period.
• Patients experiencing out-of-hospital cardiac ar-
rest during COVID-19 were less likely to receive 
guideline-indicated care and had increased 
mortality compared with the pre–COVID-19 era.
What Are the Clinical Implications?
• Immediate countermeasures are required to in-
crease patient awareness and improve cardiac 
care of this high-risk group during the ongoing 
COVID-19 pandemic.
Nonstandard Abbreviations and Acronyms
BCIS British Cardiovascular Intervention 
Society
COVID-19 coronavirus disease 2019
IRR incidence rate ratio
MINAP Myocardial Ischaemia National Audit 
Project
OHCA out-of-hospital cardiac arrest
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2006,24,25 and therefore institutional board review was 
not required for this study. Access to data required for 
this project has been fast tracked using a novel col-
laboration as part of a national drive for COVID-19–re-
lated research.
Study Population
We included all adult patients, aged 18 to 100  years, 
admitted with a diagnosis of AMI between February 
1, 2019, and May 14, 2020 (the latest live data upload 
available), from the MINAP registry and BCIS registry 
PCI database. We only included patients with an index 
admission diagnosis of AMI or a PCI procedure during 
these dates. Further exclusions were made on the basis 
of missing record information on sex, cardiac arrest in 
hospital, and final diagnosis not being AMI (Figures S1 
and S2). Given that first cases of COVID-19 in the United 
Kingdom were reported on January 29, 2020, we de-
fined patients from February 1, 2020, to May 14, 2020, as 
the COVID-19 group. To further understand the tempo-
ral differences in the baseline characteristics, procedural 
profile, and outcomes, we generated an equivalent co-
hort of pre–COVID-19 patients from February 1, 2019, to 
May 14, 2019, from both data sets. Time to reperfusion 
treatment was calculated from time of symptom onset to 
time of the reperfusion treatment in the form of primary 
PCI or thrombolysis for ST-segment–elevation AMI.
Statistical Analysis
Continuous variables were presented as means and 
SDs, whereas categorical variables were reported 
as absolute numbers and percentages. The χ2 and 
Student t-tests were used to examine differences 
across groups for categorical and continuous vari-
ables, respectively. All statistical comparisons were 
made between the pre–COVID-19 and COVID-19 
groups only, whereas patients without OHCA were 
reported for total cohort comparison. All tests were 
2 sided, and P<0.05 was considered statistically 
significant. Poisson regression models were used 
to estimate the unadjusted incidence rate ratio (IRR) 
of OHCA across each month of 2020, using the 
equivalent month in 2019 as the reference. We used 
multiple imputations with chained equations to ac-
count for missing data-related bias, creating 10 data 
sets.26,27 Variables with complete information, such 
as age, sex, OHCA, month, and year, were registered 
as regular, whereas all other variables with missing 
information were imputed using logistic regression 
for binary, multinomial for nominal, and linear regres-
sion for continuous variables (Table  S1). We used 
multivariable logistic regression with an interaction 
term between OHCA and the month variable to study 
the association between OHCA and in-hospital mor-
tality in the pre–COVID-19 and COVID-19 periods. 
The margins command was using following the re-
gression models, to obtain adjusted probability for 
in-hospital mortality.
To investigate whether the lag in the data uploads 
may be associated with inflated incidence of OHCA 
because of different hospital reporting pre–COVID-19 
and post–COVID-19 period, we performed a sensitiv-
ity analysis. We only included the 88 “rapid reporting” 
hospitals that have consistently provided data on a 
weekly basis during the COVID-19 and pre–COVID-19 
period across 2019 and 2020. All analyses were per-
formed using Stata v16.0.
RESULTS
Clinical Characteristics
Five hundred twenty-four patients (5.6%) were ad-
mitted with OHCA from a total of 9325 AMI admis-
sions the during the COVID-19 period from February 
1, 2020, to May 14, 2020, compared with 731 (3.6%) 
patients of 20 310 during the equivalent pre–COVID-
19 period from February 1, 2019, to May 14, 2019. 
Patients presenting with OHCA during the COVID-19 
period were older (mean age, 67.1 versus 63.1 years; 
P<0.001), were more often women (28.8% versus 
20.5%; P<0.001), and were more often of Asian 
ethnicity (10.0% versus 4.6%; P<0.001). There was 
an increased prevalence of insulin-treated diabetes 
mellitus (6.4% versus 3.0%; P<0.001) and hyperten-
sion (47.9% versus 41.2%; P<0.001) in the COVID-
19 OHCA group compared with the pre–COVID-19 
OHCA group. In-hospital pharmacological treat-
ments were comparable between the pre–COVID-19 
and COVID-19 groups, with similar use of glycopro-
tein IIb/IIIa inhibitors, angiotensin-converting enzyme 
inhibitors, P2Y12 inhibitors, and dual antiplatelet 
therapy (Table  1). An increasing proportion of pa-
tients with OHCA during the COVID-19 period had 
ST-segment–elevation myocardial infarction com-
pared with patients experiencing OHCA in the pre–
COVID-19 period (Figure S3).
Trends in Incidence of OHCA
During the COVID-19 period, the monthly proportions 
of OHCA increased from 5.4% in February 2020 to 
6.9% in May 2020 (Figure  1), whereas there was a 
significant decrease in the total number of patients 
presenting with AMI. There was a 56% increase in 
the overall incidence of OHCA during the COVID-19 
period (5.6% versus 3.6%; IRR, 1.56; 95% CI, 1.39–
1.74) compared with pre–COVID-19 period (Figure 2). 
The IRR of OHCA also increased from 1.55 (95% CI, 
1.29–1.87) in February 2020 to 1.96 (95% CI, 1.31–
2.86) in May 2020 compared with equivalent monthly 
periods in 2019 (Figure 2). In the sensitivity analysis 
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Table 1. Baseline Characteristics of All Patients Presenting With OHCA Admitted With AMI Before and During the 
COVID-19 Pandemic in England
Variables





Group (N=524) P Value*
Age, mean (SD), y 68.2 (13.6) 63.1 (12.2) 67.1 (13.2) <0.001
Men, n (%) 19 295 (68.0) 581 (79.5) 373 (71.2) <0.001
Race, n (%) 0.008
White 20 039 (86.7) 530 (89.4) 350 (83.7)
Black 368 (1.6) 7 (1.2) 5 (1.2)
Asian 1930 (8.3) 27 (4.6) 42 (10.0)
Mixed 787 (3.4) 29 (4.9) 21 (5.0)
Presenting characteristics
BMI, mean (SD), kg/m2 28.2 (5.9) 27.6 (4.9) 28.1 (5.7) 0.15
Heart rate, mean (SD), bpm 78.8 (19.4) 86.3 (24.2) 84.6 (24.2) 0.22
Systolic blood pressure, mean (SD), mm Hg 140.2 (27.5) 124.5 (30.4) 125.7 (29.4) 0.51
Clinical syndrome 0.62
STEMI, n (%) 8867 (31.2) 538 (73.6) 379 (72.3)
NSTEMI, n (%) 19 513 (68.8) 193 (26.4) 145 (27.7)
Creatinine (μmol/L), mean (SD) 97.1 (64.9) 102.5 (49.3) 107.8 (69.9) 0.13
Peak troponin level (ng/l), median (IQR) 266 (43–1771) 596 (40–4722) 380 (23–4081) <0.001
Killip class, n (%) 0.17
No heart failure 21 946 (84.6) 410 (65.8) 301 (66.2)
Basal crepitation 2599 (10.0) 70 (11.2) 44 (9.7)
Pulmonary edema 1037 (4.0) 27 (4.3) 33 (7.3)
Cardiogenic shock 371 (1.4) 116 (18.6) 77 (16.9)
LV systolic function, n (%) 0.007 
Good 10 499 (45.7) 182 (30.1) 121 (28.9)
Moderate 5785 (25.2) 233 (38.5) 141 (33.7)
Poor 1795 (7.8) 108 (17.9) 66 (15.8)
Not assessed 4894 (21.3) 82 (13.6) 91 (21.7)
Medical history, n (%)
Percutaneous coronary intervention 4187 (16.8) 66 (10.6) 49 (11.4) 0.68
Coronary artery bypass grafting 1740 (7.0) 28 (4.5) 29 (6.7) 0.12
Heart failure 1833 (7.3) 34 (5.5) 30 (7.0) 0.33
Hypercholesterolemia 8147 (32.6) 151 (24.6) 107 (24.9) 0.90
Angina 5193 (20.8) 53 (8.6) 55 (12.9) 0.02
Cerebrovascular disease 2042 (8.4) 86 (7.8) 25 (6.1) 0.14
Myocardial infarction 6015 (23.8) 94 (15.1) 83 (19.2) 0.07
Peripheral vascular disease 1100 (4.4) 16 (2.6) 14 (3.2) 0.54
Chronic kidney disease 3027 (11.9) 91 (14.4) 73 (16.4) 0.37
Diabetes mellitus, n (%) <0.001
Not diabetic 20 019 (72.6) 575 (85.3) 361 (76.6)
Diet controlled 1208 (4.4) 12 (1.8) 26 (5.5)
Oral medications 4112 (14.9) 67 (9.9) 54 (11.5)
Insulin therapy 2234 (8.1) 20 (3.0) 30 (6.4)
Hypertension 13 850 (54.5) 254 (41.2) 209 (47.9) 0.02
Smoking status, n (%) 0.25
Never smoked 8264 (35.6) 156 (31.1) 130 (36.4)
Previous smoker 8475 (36.5) 148 (29.5) 94 (26.3)
 (Continued)
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of “rapid reporting,” hospitals that consistently re-
ported data in all months during pre–COVID-19 and 
COVID-19 periods, we found a similar increase in 
the incidence of OHCA in patients presenting with 
AMI during the COVID-19 period (IRR, 1.36 [95% CI, 
1.08–1.72] in February 2020, increasing to IRR, 1.80 
[95% CI, 1.20–2.99] in May 2020) compared with the 
pre–COVID-19 period (Figures S4 and S5).
Variables





Group (N=524) P Value*
Current smoker 6503 (28.0) 198 (39.4) 133 (37.3)
Asthma/COPD 4444 (17.8) 88 (14.3) 71 (16.6) 0.31
Family history of CHD, n (%) 6067 (28.5) 87 (16.6) 60 (17.0) 0.87
In-hospital pharmacology, n (%)
Low-molecular-weight heparin 9130 (42.4) 340 (60.7) 184 (50.8) 0.003
Unfractionated heparin 7001 (32.3) 286 (50.9) 153 (41.5) 0.005
Warfarin 718 (3.3) 20 (3.6) 11 (3.0) 0.63
Loop diuretic 5054 (23.4) 162 (29.2) 118 (32.2) 0.35
Glycoprotein IIb/IIIa inhibitor use 1435 (6.6) 93 (16.5) 69 (18.7) 0.38
Processes of care
Seen by cardiologist, n (%) 27 381 (97.7) 690 (96.8) 457 (91.0) <0.001
Coronary angiography, n (%) 16 918 (77.9) 305 (71.6) 177 (58.4) <0.001
Percutaneous coronary intervention, n (%) 9635 (56.3) 176 (43.7) 102 (42.9) 0.84
Time to reperfusion, mean (SD), h 3.0 (14.6) 1.1 (1.4) 2.1 (11.5) 0.05
P2Y12 use, n (%) 25 629 (90.3) 553 (75.6) 378 (72.1) 0.16
Dual-antiplatelet therapy, n (%) 24 936 (87.9) 525 (71.8) 364 (69.5) 0.37
ACE inhibitors, n (%) 15 702 (70.7) 338 (58.8) 197 (52.4) 0.26
In-hospital mortality, n (%) 778 (2.8) 201 (27.8) 192 (37.7) <0.001
The COVID-19 period was from February 1, 2020, to May 14, 2020; and the pre–COVID-19 period was from February 1, 2019, to May 14, 2019. The UK 
lockdown was on March 22, 2020. ACE indicates angiotensin-converting enzyme; AMI, acute myocardial infarction; BMI, body mass index; bpm, beats per 
minute; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; IQR, interquartile range; LV, left 
ventricle; NSTEMI, non–ST-segment–elevation myocardial infarction; OHCA, out-of-hospital cardiac arrest; and STEMI, ST-segment–elevation myocardial 
infarction.
*All statistical comparisons were made between pre–COVID-19 period and COVID-19 period groups only.
Table 1. Continued
Figure 1. Temporal trends of monthly proportions of patients with acute 
myocardial infarction presenting with out-of-hospital cardiac arrest (OHCA) 
before and during coronavirus disease 2019 (COVID-19) pandemic in England.
COVID-19 period indicates February 1, 2020, to May 14, 2020; pre–COVID-19 period, 
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Processes of Care
Patients admitted with OHCA during the COVID-19 
period were slightly less likely to be seen by a car-
diologist (91.0% versus 96.8%; P<0.001), less likely 
to be investigated with invasive coronary angiogra-
phy (58.4% versus 71.6%; P<0.001), and, for those 
with ST-segment–elevation myocardial infarction, 
had increased time to reperfusion treatment (mean, 
2.1  versus 1.1  hour; P=0.05) (Table  1). Temporal 
analysis of use of invasive coronary angiography re-
vealed a consistent lower use of an invasive strategy 
across all months in the COVID-19 period, with al-
most a 50% reduction in May 2020 compared with 
May 2019 (Figure 3). The use of PCI was also lower 
across COVID-19 months in 2020 compared with 
pre–COVID-19 months in 2019 (Figure S6). In-hospital 
mortality was higher in the OHCA group during the 
COVID-19 period compared with pre–COVID-19 
(37.7% versus 27.8%; P<0.001). In the multivariable 
analysis, the adjusted probability of mortality also in-
creased from 27.7% to 35.8% in the COVID-19 cohort 
compared with 16.9% to 29.8% in the pre–COVID-19 
cohort (P<0.001) (Figure S7).
Clinical and Angiographic Characteristics 
From BCIS Registry
In the BCIS registry, of 15  114 PCI procedures, 
674 (4.5%) were undertaken for OHCA in the 
pre–COVID-19 period compared with 270 (3.4%) 
of 7856 during the COVID-19 period. The baseline 
demographics and clinical characteristics were 
similar between the pre–COVID-19 and COVID-
19 periods (Table  2). Patients with OHCA who 
received PCI during the COVID-19 period more 
frequently had complex coronary disease, such as 
left main stem (3.8% versus 1.2%; P<0.001) and 
multivessel PCI (21.2% versus 12.6%; P<0.001). 
There was similar use of periprocedural pharma-
cology, hemodynamic support in the form of phar-
macological inotropes, intra-aortic balloon pump, 
and Impella device across the pre–COVID-19 and 
COVID-19 groups (Table S2). The procedural suc-
cess was similar in both groups, with no difference 
in the in-hospital mortality, major adverse cerebro-
vascular events, bleeding, and other periproce-
dural complications (Table S2).
DISCUSSION
In this national prospective cohort of patients hospi-
talized with AMI during the COVID-19 outbreak, there 
was an increase in the incidence of OHCA accompa-
nied with a substantial decline in AMI-related hospitali-
zations during the same time period. In fact, following 
announcement of lockdown and implementation of 
social distancing measures in England, the incidence 
of OHCA among those presenting with AMI almost 
Figure 2. Monthly incidence of out-of-hospital cardiac arrest related hospitalizations during the 
coronavirus disease 2019 (COVID-19) period compared with pre–COVID-19 period in England.
COVID-19 period indicates February 1, 2020, to May 14, 2020; pre–COVID-19 period, February 1, 2019, to 
May 14, 2019; and UK lockdown, March 22, 2020.
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doubled in the late phase of COVID-19 pandemic com-
pared with an equivalent period in the previous year. 
More frequently, patients presenting with OHCA during 
the COVID-19 period were older, women, and of Asian 
ethnicity. Although the pharmacological management 
strategies were not changed, during the COVID-19 
pandemic, patients hospitalized with AMI after OHCA 
had longer delays to emergency reperfusion, less fre-
quently received invasive coronary angiography, were 
less likely to receive specialist care, and had a higher 
risk of in-hospital death.
Many studies have noticed a decrease in AMI-
related admissions during COVID-19 pandemic.2–4,28 
Data from 15 hospitals in the northern Italy revealed 
>30% reduction in the incidence of AMI-related hos-
pitalizations during the COVID-19 pandemic.29 Similar 
observations were made by Mafham et al from England, 
reporting 40% reduction in AMI-related hospitalizations 
during the COVID-19 pandemic.28 The slight difference 
between the incidence of AMI-related hospitalizations 
in this study may be related to differences in data sets 
and coding differences in the Secondary Uses Service 
Admitted Patient Care data set that was used.28 These 
findings have raised concerns that the decrease in 
AMI admissions may have resulted in an increased 
risk of OHCA, mortality, or both. Our study substan-
tiates these concerns by showing reduced AMI ad-
missions paralleled an increased incidence of OHCA 
among those presenting with AMI during the COVID-
19 pandemic in England. These results are consistent 
with those of Baldi et al, who reported a 58% increase 
in the incidence of OHCA among COVID-19–positive 
patients in Italy.12 However, there were no data about 
the concurrent history of coronary heart disease or 
AMI diagnosis in these patients, and the authors con-
cluded that these findings may be related to actual viral 
infection.
Our data provide important information about 
the characteristics and in-hospital management 
of patients experiencing OHCA during the COVID-
19 pandemic. The demographic differences in the 
prepandemic and during COVID-19 period are of 
particular interest. It is possible that older patients 
with increased comorbidities may have refrained 
from seeking early help because of fears of being 
exposed to infection, breaking their shielding and so-
cial confinement. Our observation about the ethnic 
origin of patients experiencing OHCA may be linked 
to increased risk of COVID-19–related mortality in 
ethnic minorities, such as south Asians, that has 
been widely reported.30,31 It is probable that media 
coverage, cultural and social beliefs, and a lack of 
awareness may have prompted many to delay con-
tact with the emergency medical services, thus pre-
senting with OHCA.
There were also differences in in-hospital man-
agement and outcomes of patients experiencing 
OHCA during the COVID-19 period. Patients with 
OHCA during the COVID-19 period experienced an 
increase in time to reperfusion therapy and slightly 
Figure 3. Temporal trends in rates of coronary angiography use in management of patients with 
out-of-hospital cardiac arrest (OHCA) before and during coronavirus disease 2019 (COVID-19) 
pandemic in England.
COVID-19 period indicates February 1, 2020, to May 14, 2020; pre–COVID-19 period, February 1, 2019, to 
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less specialist care and use of invasive coronary strat-
egy, whereas the demographics of those selected 
for PCI seem to have been unchanged. Following 
government directives and a declaration of a health-
care emergency in the United Kingdom, hospitals 
undertook major reconfigurations of their services in 
preparation for COVID-19–related admissions. It is 
possible that the restructuring of emergency services, 
redeployment of specialist physicians to COVID-19 
wards to focus on the care of COVID-19–positive 
patients, and conflicting and evolving guidance on 
how and when to resuscite in the context of OHCA, 
specifically with concerns about the aerosol gen-
eration, may have contributed to these differences 
Table 2. Baseline Characteristics of All Patients Presenting With OHCA Undergoing PCI Before and During the COVID-19 
Pandemic in England
Variables






Age, mean (SD), y 65.3 (12.2) 62.3 (12.2) 63.0 (11.7) 0.41
Men, n (%) 16 273 (73.9) 534 (79.2) 212 (78.5) 0.81
Race 0.49
White 14 849 (83.9) 471 (89.0) 201 (91.0)
Black 235 (1.3) 5 (0.9) 0 (0.0)
Asian 1767 (10.0) 26 (4.9) 9 (4.1)
Others 854 (4.8) 27 (5.1) 11 (5.0)
BMI, mean (SD), kg/m2 28.4 (5.4) 27.9 (4.9) 27.7 (5.3) 0.61
Previous PCI, n (%) 5150 (23.7) 90 (13.7) 35 (13.5) 0.95
Previous CABG, n (%) 1134 (5.2) 18 (2.7) 5 (1.9) 0.47
Previous AMI, n (%) 5032 (23.1) 96 (15.1) 36 (14.0)
CVA, n (%) 887 (4.2) 27 (4.5) 0 (0.0) <0.001
Renal disease, n (%) 4711 (21.7) 163 (25.3) 114 (43.2) <0.001
Hypercholesterolemia, n (%) 9403 (44.6) 207 (34.3) 48 (20.8) <0.001
PVD, n (%) 754 (3.6) 23 (3.8) 9 (3.9) 0.96
Smoking history, n (%) 0.19
Never smoked 8118 (40.4) 208 (40.5) 92 (47.9)
Ex-smoker 6823 (33.9) 135 (26.3) 42 (21.9)
Current smoker 5163 (25.7) 171 (33.3) 58 (30.2)
Diabetes mellitus, n (%) 5292 (24.4) 91 (14.6) 29 (11.8) 0.28
Hypertension, n (%) 11 527 (54.7) 230 (38.1) 85 (36.8) 0.72
LV systolic function, n (%) 0.12
Good 18 188 (82.6) 452 (67.1) 195 (72.2)
Moderate 3073 (14.0) 145 (21.5) 42 (15.6)
Severe 746 (3.4) 77 (11.4) 33 (12.2)
Indication for intervention, n (%) 0.63
STEMI 13 257 (63.4) 122 (18.3) 52 (19.7)
NSTEMI/ACS 7647 (36.6) 543 (81.7) 212 (80.3)
Arterial blood gas PH, mean (SD) 7.22 (0.16) 7.19 (0.15) 7.23 (0.13) 0.07
Base excess, mean (SD) −3.72 (7.8) −3.74 (8.0) −3.45 (8.3) 0.72
Cardiogenic shock, n (%) 1475 (6.7) 233 (34.6) 89 (33.0) 0.64
Glasgow Come Scale score, n (%) 0.55
15 1011 (95.1) 148 (36.7) 70 (39.3)
<8 52 (4.9) 255 (63.3) 108 (60.7)
Mechanical ventilation, n (%) 26 (1.3) 338 (56.6) 132 (55.5) 0.76
The COVID-19 period was from February 1, 2020, to May 14, 2020; and the pre–COVID-19 period was from February 1, 2019, to May 14, 2019. The UK 
lockdown was on March 22, 2020. ACS indicates acute coronary syndrome; AMI, acute myocardial infarction; BMI, body mass index; CABG, coronary 
artery bypass grafting; COVID-19, coronavirus disease 2019; CVA, cerebrovascular accident; LV, left ventricle; NSTEMI, non–ST-segment–elevation myocardial 
infarction; OHCA, out-of-hospital cardiac arrest; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; and STEMI, ST-segment–elevation 
myocardial infarction.
*All statistical comparisons were made between pre–COVID-19 period and COVID-19 period groups only.
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in management.32,33 Indeed, we noted a significant 
reduction in invasive coronary strategy for OHCA in 
this study, which is associated with improved survival 
and more favorable neurological outcomes, particu-
larly in those presenting with ST-segment elevation 
on the ECG.34 Reassuringly, we observed no sub-
stantial differences in procedural characteristics and 
outcomes for patients with OHCA who received PCI 
during the COVID-19 period.
To the best of our knowledge, this is first national 
report of impact of COVID-19 pandemic on the care 
and outcomes of patients with OHCA presenting to 
hospitals in the setting of AMI. We acknowledge the 
limitation of our study. The MINAP registry collects 
data only for hospitalized cases of acute coronary 
syndrome, and we were therefore unable to inves-
tigate the incidence, care, and outcomes of those 
with OHCA occurring in patients in whom OHCA 
was not related to an acute coronary syndrome or 
who did not survive to hospital admission. Therefore, 
our data are likely to have underestimated the over-
all incidence of OHCA. Nevertheless, a recent report 
from a community cardiac arrest registry suggested 
a similar increase in OHCA incidence, reaffirming 
our findings.12 Finally, the observational nature of our 
study precludes inferences about causation.
CONCLUSIONS
Our study provides important insight into admissions, 
care, and outcomes for patients with AMI complicated 
by OHCA during the COVID-19 pandemic. These data 
suggest that a decline in AMI-related hospitalization in 
England was accompanied by an increase in the number 
of cases of OHCA, particularly after the implementation 
of social confinement measures during the COVID-19 
outbreak in England. It appears that elderly people, 
women, and ethnic minorities may have refrained from 
seeking early help after developing cardiac symptoms 
of AMI. The reorganization of hospital services and staff 
in preparation for the COVID-19 pandemic may inad-
vertently have affected the care of this high-risk group. 
Urgent interventions to improve public awareness and 
treatment pathway to allow timely access to specialist 
care will be required to minimize the collateral cardiac 
damage of COVID-19 for patients with AMI.
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Race 5,500 (18.5%) 
BMI  0 
Heart rate 0 
Systolic blood pressure 0 
Clinical syndrome 0 
Creatinine 0 
Kilip Class 2,604 (8.8%) 
LV systolic function 5,638 (19.0%) 
Percutaneous coronary intervention 3,702 (12.5%) 
Coronary artery bypass graft 3,705 (12.5%) 
Heart failure 3,568 (12.0%) 
Hypercholesterolemia 3,574 (12.0%) 
Angina 3,641 (12.3%) 
Cerebrovascular disease 3,643 (12.3%) 
Myocardial infarction  3,333 (11.3%) 
Peripheral vascular disease 3,692 (12.5%) 
Chronic kidney disease 3,204 (10.8%) 
Diabetes 917 (3.0%) 
Hypertension 3,168 (10.7%) 
Smoking status 5,534 (18.7%) 
Asthma / COPD 3,557 (12.0%) 
Family history of CHD 7,462 (25.2%) 
Low molecular weight heparin 7,177 (24.2%) 
Unfractionated heparin  7,045 (23.8%) 
Warfarin 7,270 (24.5%) 
Loop Diuretic 7,085 (23.9%) 
Glycoprotein use 6,891 (23.2%) 
Seen by cardiologist 381 (1.3%) 
Coronary angiography 3,523 (11.9%) 
Percutaneous coronary intervention   9,677 (32.6%) 
P2Y12 use 0 
Dual antiplatelet therapy  0 
ACE inhibitors 6,480 (21.9%) 
In-hospital mortality  0 
 
CHD= coronary heart disease, COPD= chronic obstructive pulmonary disease, LV= left ventricle, bpm= beats per minute, 
BMI= body mass index, OHCA= out of hospital cardiac arrest, UK lockdown= 22nd March 2020, COVID19 = Corona virus 
infection. Pre-COVID19 period= 1st February 2019 to 14th May 2019, COVID19 period= 1st February 2020 to 14th May 
2020 
 
Table S2. Procedural characteristic of patients presenting with OHCA undergoing PCI before 
and during COVID-19 pandemic. 










Lesion attempted    0.26 
1 14,965(68.9%) 480 (71.8%) 216 (81.2%)  
2 4171 (19.2%) 129 (19.3%) 31 (11.6%)  
3 or more 1442 (6.6%) 50 (7.5%) 16 (6.2%)  
Call to Balloon time 8.8 (18.9) 2.5 (4.5) 3.2 (5.9) 0.12 
Vessel attempted    0.05 
Grafts 357 (1.7%) 7 (1.1%) 2 (0.8%)  
LMS 485 (2.3%) 8 (1.2%) 10 (3.8%)  
RCA 9314 (45.0%) 367 (55.8%) 145 (54.5%)  
LAD 3925 (19.0%) 113 (17.2%) 35 (13.2%)  
LCX 6608 (31.9%) 163 (24.8%) 74 (27.8%)  
Multi-vessel PCI 4200 (19.1%) 85 (12.6%) 44 (21.2%) <0.001 
Number of stents    0.26 
0 3221 (14.9%) 72 (10.8%) 37 (14.1%)  
1 11301 (52.4%) 376 (56.6%) 153 (58.4%)  
2 4755 (22.1%) 138 (20.8%) 50 (19.1%)  
3 or more 2278 (10.6%) 78 (11.7%) 22 (8.4%)  
Inotropic support 334 (1.6%) 113 (17.4%) 37 (14.2%) 0.23 
Intra-aortic balloon 
pump 
127 (0.6%) 49 (7.6%) 16 (6.1%) 0.45 
Impella 16 (0.1%) 1 (0.2%) 1 (0.4%) 0.50 
Glyoprotein IIb/IIIa 
inhibitor use 
3075 (16.2%) 243 (40.7%) 99 (42.1%) 0.71 
TIMI flow post PCI     0.64 
0 431 (3.0%) 34 (6.5%) 15 (7.3%)  
1 120 (0.8%) 5 (1.0%) 3 (1.5%)  
2 419 (2.9%) 25 (4.8%) 6 (2.9%)  
3 13529 (93.3%) 460 (87.8%) 182 (88.3%)  
IVUS use 1946 (9.8%) 44 (7.4%) 24 (10.0%) 0.22 
OCT use 726 (3.7%) 21 (3.5%) 11 (4.6%) 0.48 
FFR/iFR use 2236 (11.3%) 15 (2.5%) 5 (2.1%) 0.71 
Aspirin  17585 (93.6%) 442 (78.4%) 175 (76.4%) 0.55 
Clopidogrel  7451 (40.9%) 130 (24.2%) 47 (21.2%) 0.37 
Ticagrelor 8079 (44.3%) 186 (34.6%) 80 (36.0%) 0.70 
Heparin 4502 (24.7%) 142 (26.4%) 64 (28.8%) 0.49 
Procedural outcomes      
MACCE 615 (2.9%) 151 (23.2%) 42 (17.0%) <0.001 
In-hospital bleeding 92 (0.4%) 10 (2.0%) 2 (1.0%) 0.34 
In-hospital death  316(1.4%) 136 (20.2%) 40 (14.8%) 0.05 
*All statistical comparisons were made between pre-COVID19 and COVID-19 period group only, 
LMS= left main stem, RCA= Right coronary artery, LAD= left anterior descending artery, LCX= left 
circumflex artery, IVUS= intravascular ultrasound, OCT= optical coherence tomography, FFR= 
fractional flow reserve, iFR= instantaneous flow reserve, MACCE= major adverse cerebrovascular 
events. 









Figure S3. Temporal trends of monthly proportions of OHCA patients presenting with STEMI 
before and during COVID19 period.   
 
OHCA= out of hospital cardiac arrest, UK lockdown= 22nd March 2020, COVID19 = Corona virus infection. Pre-COVID19 
period= 1st February 2019 to 14th May 2019, COVID19 period= 1st February 2020 to 14th May 2020, STEMI= st elevation 






































Figure S4. Temporal trends of monthly proportion of patients presenting with OHCA before 
and during the COVID-19 pandemic amongst the rapid reporting hospitals.  
  
OHCA= out of hospital cardiac arrest, UK lockdown= 22nd March 2020, COVID19 = Corona virus infection. Pre-COVID19 




































Figure S5. Incidence rate ratio of OHCA during COVID-19 pandemic amongst the rapid 
response hospitals. 
 
OHCA= out of hospital cardiac arrest, UK lockdown= 22nd March 2020, COVID19 = Corona virus infection. Pre-COVID19 
period= 1st February 2019 to 14th May 2019, COVID19 period= 1st February 2020 to 14th May 2020 
 
Figure S6. Temporal trends of use of percutaneous coronary intervention before and during 
COVID19 period in England. 
 
OHCA= out of hospital cardiac arrest, UK lockdown= 22nd March 2020, COVID19 = Corona virus infection. Pre-COVID19 




































Figure S7. Monthly adjusted probability of mortality between pre-COVID-19 and COVID-19 
OHCA groups in England. 
 
OHCA= out of hospital cardiac arrest, UK lockdown= 22nd March 2020, COVID19 = Corona virus infection. Pre-COVID19 
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